Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract
- PMID: 16331503
- DOI: 10.1007/s00345-005-0017-3
Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract
Abstract
To date, it is widely accepted that several disorders of the male and female urogenital tract, such as erectile dysfunction, bladder overactivity, urinary stone disease and the benign prostatic syndrome, can be therapeutically approached by influencing the function of the smooth musculature of the respective organs. In order to achieve a pronounced drug effect without significant adverse events, especially on the cardiovascular system, a certain degree of tissue selectivity is mandatory. Selective intervention in intracellular pathways regulating smooth muscle tone has become a promising strategy to modulate tissue function. Since the concept of taking a pill as a cure for an illness or the relief of symptoms has become widely accepted by the consumers, the pharmacological treatment of urological diseases has focused on selective, orally available drugs, acting via influencing intracellular regulatory mechanisms, thus combining a high response rate and the advantage of an on-demand intake. PDEs play a central role in controlling the levels of cyclic nucleotides (i.e. cAMP and/or cGMP), which are important second messengers in many transmitter pathways involved in the regulation of biological processes of urogenital tissues. Specifically, the use of isoenzyme selective phosphodiesterase (PDE) inhibitors offers great hope in the medical treatment of various genitourinary diseases. These agents are regarded efficacious, having a fast onset of drug action in the target tissue and an improved effect-to-side-effect ratio. The growing experience with the use of this class of compounds in urology is mainly based on basic research efforts and this field will remain the most exciting and innovative subject in genitourinary physiology and pharmacology for the next few years. These tremendous research efforts may lead to a vast pharmacological armamentarium of possible new treatment options. The purpose of this review is to summarize the current knowledge on the distribution and potential functional significance of PDE isoenzymes in the human lower urinary tract.
Similar articles
-
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.Handb Exp Pharmacol. 2011;(204):307-22. doi: 10.1007/978-3-642-17969-3_13. Handb Exp Pharmacol. 2011. PMID: 21695646 Review.
-
Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.Handb Exp Pharmacol. 2011;(202):527-42. doi: 10.1007/978-3-642-16499-6_23. Handb Exp Pharmacol. 2011. PMID: 21290241 Review.
-
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.Eur Urol. 2006 Dec;50(6):1194-207; discussion 1207. doi: 10.1016/j.eururo.2006.05.025. Epub 2006 Jun 6. Eur Urol. 2006. PMID: 16815627 Review.
-
Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.Neurourol Urodyn. 2007 Oct;26(6 Suppl):928-33. doi: 10.1002/nau.20485. Neurourol Urodyn. 2007. PMID: 17806124 Review.
-
Phosphodiesterase inhibitors in clinical urology.Expert Rev Clin Pharmacol. 2013 May;6(3):323-32. doi: 10.1586/ecp.13.16. Expert Rev Clin Pharmacol. 2013. PMID: 23656343 Review.
Cited by
-
[Pathophysiology and therapy of benign prostatic hyperplasia].Wien Klin Wochenschr. 2008;120(13-14):390-401. doi: 10.1007/s00508-008-0986-5. Wien Klin Wochenschr. 2008. PMID: 18726663 Review. German.
-
New insights into the pharmacology of the bladder.Curr Opin Urol. 2008 Jul;18(4):347-52. doi: 10.1097/MOU.0b013e3283023bfc. Curr Opin Urol. 2008. PMID: 18520753 Free PMC article. Review.
-
Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.Drugs Aging. 2012 Sep;29(9):771-81. doi: 10.1007/s40266-012-0010-7. Drugs Aging. 2012. PMID: 23018613 Review.
-
The role of phosphodiesterases in bladder pathophysiology.Nat Rev Urol. 2013 Jul;10(7):414-24. doi: 10.1038/nrurol.2013.101. Epub 2013 May 14. Nat Rev Urol. 2013. PMID: 23670184 Review.
-
Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.Int J Gen Med. 2014 Jun 12;7:271-6. doi: 10.2147/IJGM.S40216. eCollection 2014. Int J Gen Med. 2014. PMID: 24959092 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources